Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.34 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.34 |
| ▸ | SLC6A4 | P31645 | 9/20 | 0.33 |
| ▸ | SLC6A2 | P23975 | 8/20 | 0.33 |
| ▸ | GNAI3 | P08754 | 1/20 | 0.33 |
| ▸ | GNAO1 | P09471 | 1/20 | 0.33 |
| ▸ | GNAI1 | P63096 | 1/20 | 0.33 |
| ▸ | SLC6A3 | Q01959 | 4/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | CACNA2D1 | P54289 | 2/20 | 0.32 |
| ▸ | OPRD1 | P41143 | 2/20 | 0.31 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.31 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5605219 | 0.81 | OPRD1 (0.37) | SIGMAR1CYP2D6CYP19A1SLC6A4SLC6A2 | |
| SCHEMBL28205449 | 0.81 | SLC6A3 (0.37) | SLC6A4SLC6A2SLC6A3 | |
| SCHEMBL3815697 | 0.79 | SLC6A4 (0.41) | SIGMAR1CYP2D6CYP19A1SLC6A4SLC6A2 | |
| SCHEMBL11724424 | 0.79 | SIGMAR1 (0.37) | SIGMAR1CYP2D6CYP19A1SLC6A4SLC6A2 | |
| SCHEMBL3822012 | 0.77 | SIGMAR1 (0.36) | SIGMAR1CYP2D6SLC6A4SLC6A2GNAI3 | |
| SCHEMBL6578962 | 0.77 | SIGMAR1 (0.36) | SIGMAR1CYP2D6CYP19A1SLC6A4SLC6A2 | |
| SCHEMBL23956553 | 0.76 | SLC6A4 (0.39) | SIGMAR1SLC6A4SLC6A2GNAI3GNAO1 | |
| SCHEMBL1408997 | 0.76 | SIGMAR1 (0.39) | SIGMAR1SLC6A4SLC6A2GNAI3GNAO1 | |
| SCHEMBL2116575 | 0.76 | SIGMAR1 (0.36) | SIGMAR1SLC6A4SLC6A2GNAI3GNAO1 | |
| SCHEMBL11101168 | 0.76 | SIGMAR1 (0.36) | SIGMAR1SLC6A4SLC6A2GNAI3GNAO1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6407106-B1 | FOR THERAPY OF INFLAMMATORY DISTURBANCES OF THE GASTROINTESTINAL TRACT | SOLVAY PHARMACEUTICALS GMBH (DE) | 2002-06-18 | — | — | US | disclosed |
| US-20020065276-A1 | N-triazolymethyl-piperazine compounds with neurokinin-receptor antagonist activity | SOLVAY PHARMACEUTICALS GMBH (DE) | 2002-05-30 | — | — | US | disclosed |
| CN-1020607-C | PROCESS FOR PREPARATION OF BENZOTHIAZINE DERIVS. | HOECHST AG (DE) | 1993-05-12 | — | — | CN | disclosed |
| CN-85101312-A | Process for preparing Benzothiazine derivatives | — | 1987-04-08 | — | — | CN | disclosed |
| US-3969392-A | PARASITICIDE, BACTERICIDE, ANTIINFLAMMATORY, SURFACTANT | E. R. SQUIBB & SONS, INC. (US) | 1976-07-13 | — | — | US | disclosed |
| US-3935230-A | α, α, α, α', α', α'-Hexafluorodi-m-tolylamine derivatives | E. R. SQUIBB & SONS, INC. (US) | 1976-01-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020065276-A1 | N-triazolymethyl-piperazine compounds with neurokinin-receptor antagonist activity | NPSR1, NTSR2, NTSR1 | SIGMAR1 134/4885CYP2D6 3967/4885CYP19A1 1801/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.